Synthetic Dermocosmetic Portfolio: Pharmaceutical-Grade Development Dossier

Design basis: fully synthetic (defined chemical entities only) · pharmaceutical CMC standards (ICH Q8/Q1A/Q3D, USP <51>/<61>/<62>, ISO 22716) · target Yuka score ≥95 on every SKU

Status: Formulation design package, pre-benchtop. All formulas mass-balanced; none yet challenge-tested or stability-verified.

---

1. The binding constraint, stated precisely

Yuka's cosmetic score is 100% ingredient-hazard driven, presence-based, concentration-blind. Per Yuka's published penalty logic:

Therefore: ≥95 requires a 100% green INCI list. Zero yellow entries. There is no partial credit.

This is a binary combinatorial constraint, not an optimization target. It cannot be met by reducing a flagged ingredient's concentration, Yuka does not read concentration. One yellow entry at 0.05% costs the same 7 points as at 5%.

Two secondary mechanics matter:

• Short INCI penalty. Yuka applies a harsher ranking to formulas of ≤3 ingredients (a flagged ingredient represents a proportionally larger share). Every formula below carries ≥7 entries, which sidesteps this.
• Fragrance. "Parfum" without disclosure is scored cautiously; EU-declarable allergens (limonene, linalool, citral, geraniol, coumarin, eugenol) are individually flagged. The entire portfolio is fragrance-free. This is non-negotiable under a 95+ target and is the single largest formulation-freedom cost.

1.1 One SKU cannot meet the target, declared up front

RX-11 (photoprotection) has a hard ceiling of ~93, not 95+. Zinc oxide is rated low risk (yellow) by Yuka, not risk-free. Best-in-class non-nano mineral sunscreens are observed scoring 86–93 in the app, exactly what the −7 yellow-irritant penalty predicts. Titanium dioxide scores worse (nano/inhalation carcinogenicity flags). Every organic filter, octocrylene, homosalate, ethylhexyl salicylate, avobenzone, ethylhexyl methoxycinnamate, is orange or red, capping at 49. Next-generation filters (bemotrizinol/Tinosorb S, DHHB, Mexoryl 400) are gold-standard UVA photoprotectants and are either flagged or unrated.

There is no chemistry that yields a ≥95 Yuka score with meaningful broad-spectrum photoprotection. The correct decision is to break the target on this one SKU rather than ship inadequate UVA protection, and to state the 93 openly. Photoprotection is the single highest-evidence intervention in the entire portfolio for both photoaging and carcinoma risk; sacrificing it to an app score would invert the portfolio's own efficacy premise.

1.2 "Fully synthetic", operative definition

Every ingredient is a single defined chemical entity or defined polymer with a specification and CoA. No botanical extracts, no essential oils, no plant butters, no hydrolysates of undefined composition. Biofermentation- and biocatalysis-derived single molecules (sodium hyaluronate ex-Streptococcus, squalane ex-sugarcane, ceramide NP/AP/EOP, ectoine) qualify, they are structurally defined, not botanical mixtures.

This constraint is synergistic with both other constraints, which is why the brief is coherent:

• Yuka: eliminates the declarable-allergen problem entirely. Botanicals are the dominant source of flagged entries in "clean" formulas.
• Pharma CMC: removes botanical batch variability, geographic/seasonal assay drift, pesticide and mycotoxin residues, and the ICH Q3D elemental-impurity burden that plant material carries. Enables true assay-based release testing and a genuine design space.

---

2. Design rules

2.1 Approved excipient/active space (all green)

2.2 Prohibited (with the specific reason)

---

3. Preservation platform, the hardest technical problem in this brief

Removing phenoxyethanol, parabens, isothiazolinones, benzoate and sorbate simultaneously removes every validated broad-spectrum preservative. What remains are multifunctional glycols and glyceryl esters, which are genuine antimicrobials but are individually weak, particularly against Aspergillus brasiliensis, the hardest USP <51> challenge organism.

The pharmaceutical precedent is exact and should drive the design: preservative-free ophthalmics. The industry solved "no acceptable preservative" for BAK-free eye drops not by finding a better preservative but by engineering the system, unit-dose or airless multidose containers, low-bioburden manufacture, and in-use limits substituted for in-container preservative efficacy.

3.1 Hurdle architecture

Six independent hurdles, no single point of failure:

Hydroxyacetophenone 0.5% contributes both radical scavenging and preservative potentiation.

3.2 Honest assessment of this platform

This is the highest-risk element of the entire package and must be stated without hedging:

• The glycol/ester system routinely passes USP <51> criteria for bacteria and C. albicans and routinely fails or is marginal against A. brasiliensis at these use levels.
• Mitigation is sequential, not optional: (a) formal AET per USP <51> on every aqueous SKU at pilot scale; (b) if mould criteria fail, escalate 1,2-hexanediol to 2.0% and pentylene glycol to 5.0% and re-test; (c) if still failing, the SKU converts to airless or unit-dose with a restricted PAO (period-after-opening) and in-use stability data replacing an in-container broad-spectrum claim.
• Do not ship an aqueous SKU on this platform without passing AET. A self-preserving claim asserted without challenge data is a patient-safety issue, not a marketing risk. This is the one place where the Yuka target must yield to microbiology if the data says so.

Two SKUs sidestep the problem entirely by being anhydrous (RX-04, RX-09): a_w ≈ 0, no preservative required, no microbiological failure mode, and a clean path to a 100 score. Where a format can be made water-free, it should be, this is the highest-leverage design move available under this brief.

---

4. Portfolio architecture

Regimen logic: RX-01/02 (cleanse–prep) → RX-03/04/05/06/07 (actives, AM/PM split) → RX-08/09/10 (barrier, occlusion, periorbital) → RX-11 (AM protection) → RX-12 (body). Ten of twelve are water-based and share one preservation platform, one chelant, one buffer system and one antioxidant pair, deliberate, to collapse raw-material qualification, vendor audits and analytical method development onto a common base.

---

5. Product monographs

Notation: Aqua q.s. ad 100, water quantity shown is the calculated balance. Phases: A = water, B = oil, C = post-add (<40 °C), D = pH adjust. All % w/w.

RX-01 · Micellar Gel Cleanser

Indication: daily cleansing without barrier disruption. Design intent: total surfactant active ~2.0%, well below the irritation threshold of a conventional 8–12% system, with zero amphoteric (cocamidopropyl betaine is allergen-flagged).

Specs: pH 5.0 ± 0.3 · viscosity 4,000–8,000 cP (Brookfield RV, sp. 4, 20 rpm, 25 °C) · surfactant active 1.9–2.3% (titration) · appearance clear to slightly opalescent gel · zein number target <8 (irritation surrogate).

Process: Disperse xanthan in glycerin/propanediol premix; add to water at 60 °C under moderate shear until fully hydrated. Add remaining phase A. Cool to <40 °C, add phase C. Adjust pH with D. Deaerate. 0.2 µm filter to fill.

---

RX-02 · PHA/AHA Resurfacing Solution

Indication: keratinocyte turnover, texture, tone. Design intent: salicylic acid is flagged, so BHA keratolysis is unavailable. Substitution is gluconolactone (PHA, larger molecule, slower penetration, markedly lower stinging) as the bulk acid, with lactic acid providing free-acid titratable capacity and dermal GAG stimulation. Total acid 12%, buffered to pH 3.8, free acid value ~4.5%.

Specs: pH 3.80 ± 0.15 (tight, free-acid value is the efficacy driver and the irritation driver simultaneously) · free acid 4.0–5.0% (titration to pH 7.0) · gluconolactone assay 7.6–8.4% (HPLC-RI) · osmolality reported.

Process: Dissolve gluconolactone in water at 40 °C (note: hydrolyses to gluconic acid in solution, equilibrium is expected and is not degradation; specify assay as gluconolactone + gluconic acid sum). Add acids and polyols. Neutralize with tromethamine to target. Phase C at <35 °C.

Note: Do not co-apply with RX-04 or RX-05 in the same routine step, low pH accelerates alpha-arbutin hydrolysis (see RX-05).

---

RX-03 · Barrier + Sebum Serum (Niacinamide 10%)

Indication: barrier lipid synthesis, sebum modulation, pore appearance, early pigment. Niacinamide at 10% is the best-evidenced high-concentration green-list active available under this brief and is the portfolio's efficacy backbone.

Specs: pH 5.5 ± 0.3 · niacinamide assay 9.5–10.5% (HPLC-UV 261 nm) · nicotinic acid ≤0.05% (critical, the hydrolysis impurity causes flushing; this is the CQA that most resembles a pharmaceutical impurity limit and requires a stability-indicating method) · viscosity 2,000–5,000 cP.

Process: Dissolve niacinamide in water at ambient (endothermic; do not heat above 45 °C, hydrolysis to nicotinic acid is temperature- and pH-driven). Hydrate sclerotium gum separately. Combine. Phase C at ambient. pH is the primary control against nicotinic acid formation, hold 5.2–5.8.

---

RX-04 · Anhydrous Vitamin C (THD Ascorbate 15%)

Indication: antioxidant, collagen cofactor, pigment. Design intent: L-ascorbic acid at 15–20% is the best-evidenced form, but it requires pH ≤3.5 and is hydrolytically unstable, and its stabilization stack conventionally uses flagged excipients. Tetrahexyldecyl ascorbate is lipophilic, oil-stable, pH-independent, and converts to ascorbic acid intracellularly. An anhydrous vehicle eliminates hydrolysis and preservation simultaneously. Zero water, zero preservative, all-green: this SKU scores 100.

Specs: THDA assay 14.0–16.0% (HPLC-UV 245 nm) · free ascorbic acid ≤0.3% (hydrolysis indicator) · water content ≤0.3% (Karl Fischer, this is the critical release test; it is what makes the SKU self-preserving) · peroxide value ≤5 meq/kg · colour ≤ Gardner 3 (yellowing = degradation).

Process: Blend esters at 45 °C under nitrogen. Add THDA, mix to clarity. Add tocopherols last, below 40 °C. Nitrogen headspace overlay at fill. Opaque airless packaging.

Formulation note: Ferulic acid was evaluated and rejected, it has poor solubility in an all-ester anhydrous base and presents a recrystallization-on-storage risk. Tocopherol + tocopheryl acetate provide the redox network without that failure mode.

---

RX-05 · Pigment Corrector

Indication: melasma, PIH, photodamage-related dyschromia. Multi-pathway by necessity: hydroquinone is prohibited in cosmetics, and retinoids and the flagged acids are unavailable here, so the design attacks tyrosinase (arbutin), melanosome transfer and plasmin (TXA), and inflammatory drive (azeloyl, niacinamide) in parallel.

Specs: pH 5.0 ± 0.2, narrow window, and the reason is a genuine stability constraint: alpha-arbutin hydrolyses to hydroquinone below pH ~5, and 3-O-ethyl ascorbic acid loses activity above pH ~6. These two actives have partially conflicting stability optima and pH is the sole control point.

Critical impurity: free hydroquinone ≤10 ppm by HPLC-UV, tested at release and at every stability timepoint including 40 °C/75% RH. This is a mandatory specification, not a nice-to-have, hydroquinone is prohibited in EU cosmetics and its appearance in an arbutin formula is a known, documented degradation pathway. If accelerated stability shows hydroquinone trending above limit, α-arbutin is removed from the formula rather than the limit widened.

Process: Dissolve TXA and arbutin in water at ≤40 °C. Add azeloyl and ethyl ascorbic acid. Adjust pH before adding gum. Phase C at ambient. Nitrogen sparge; opaque airless.

---

RX-06 · Matrikine Peptide Serum

Indication: the portfolio's designated retinoid-substitute anti-aging SKU. Its honest efficacy position is set out in §8.1 and should be read before any claim is drafted against it.

Specs: pH 5.5 ± 0.3 · peptide identity/content by LC-MS/MS (each ≥80% of label at release; ≥70% at end of shelf life) · microbial control is disproportionately critical, peptides are a nitrogen source and this is the SKU most likely to fail AET. Airless, nitrogen-overlaid, 6-month PAO.

Incompatibility: copper tripeptide-1 is redox-active and is a known incompatibility with ascorbates and with high concentrations of reducing agents. Do not layer RX-06 with RX-04 or RX-05 in the same application step; alternate AM/PM. If in-use complaints or discolouration appear, copper tripeptide-1 is the first ingredient to remove.

---

RX-07 · Multi-MW HA Hydration Serum

Indication: immediate and cumulative hydration across stratum corneum depth. Four molecular weights plus polyglutamic acid give distinct depth-of-deposition and water-binding kinetics rather than a single surface film.

Specs: pH 5.5 ± 0.3 · total HA 0.70–0.80% · MW distribution confirmed by SEC-MALS at release (this is what substantiates the multi-MW claim, without it the claim is unsupported) · viscosity 1,500–4,000 cP · urea ≤1.05% with ammonia headspace monitored.

Process: Sift HA grades separately into vortex to avoid fisheyes; hydrate 45 min at ambient. Do not heat above 40 °C, HA depolymerizes and the MW distribution (the entire product premise) is lost. Add urea last in phase A at <30 °C.

---

RX-08 · Ceramide Barrier Cream

Indication: barrier repair, atopic-prone and post-procedure skin. Physiological lipid ratio (ceramide:cholesterol:free fatty acid ≈ 3:1:1), the ratio with the strongest evidence for accelerated barrier recovery rather than mere occlusion.

Specs: pH 5.2 ± 0.3 · viscosity 25,000–60,000 cP · total ceramides 0.85–0.95% (HPLC-CAD or LC-MS) · lamellar structure confirmed by cross-polarized microscopy / SAXS on the development batch, the physiological-lipid claim rests on lamellar organization, not on the ingredient list · centrifuge 3,000 rpm/30 min no separation · droplet size D50 <5 µm.

Process: Phase A to 75 °C. Phase B to 78 °C, ensuring ceramides and cholesterol fully dissolved (ceramide EOP is the limiting solubility, verify clarity before emulsification). Homogenize B into A at 75 °C, 8,000 rpm/5 min. Cool with sweep agitation. Phase C at 40 °C. Neutralize at 35 °C. Do not re-homogenize after lamellar set.

---

RX-09 · Anhydrous Repair Balm

Indication: occlusive barrier repair, post-procedure, xerotic patches. Water-free: no preservative, no microbiological failure mode, all-green, scores 100. Petrolatum is deliberately excluded (Yuka flags mineral-oil hydrocarbons); squalane plus a synthetic-polymer network replicates the occlusive function.

Specs: water ≤0.2% (Karl Fischer, release-critical) · penetrometer hardness defined range · TEWL reduction ≥40% at 4 h vs untreated (in vivo, the functional release surrogate for an occlusive) · peroxide value ≤5 meq/kg · no syneresis at 40 °C/8 weeks.

Process: Melt structured components at 85 °C until fully dispersed. Add ceramides/cholesterol, hold to clarity. Cool under vacuum with slow sweep to 45 °C; tocopherol and phytosphingosine at 45 °C. Fill at 42–45 °C into tubes or jars. Controlled cooling rate is the CPP, it sets crystal habit and therefore texture and syneresis behaviour.

---

RX-10 · Eye Contour Gel-Cream

Indication: periorbital puffiness, dark circles, fine lines. Low lipid load and low viscosity to prevent migration into the eye; ocular tolerance testing is mandatory given the anatomy and the absence of a conventional preservative.

Specs: pH 5.5 ± 0.3 · caffeine assay 2.85–3.15% (HPLC-UV 273 nm) · viscosity 8,000–20,000 cP · osmolality 280–400 mOsm/kg (ocular-adjacent, hypotonic or strongly hypertonic product stings and increases lacrimation) · HET-CAM or reconstructed-cornea ocular irritation: non-irritant · unit-dose or airless mandatory, PAO ≤6 months.

---

RX-11 · Mineral SPF 30 Fluid (declared exception: Yuka ~93)

Indication: daily broad-spectrum photoprotection. In the US this is an OTC monograph drug, not a cosmetic, see §9.2. Zinc oxide non-nano at 20% is the ceiling of what is cosmetically acceptable; non-nano particle size costs UV-attenuation efficiency per unit mass relative to nano grades, which is why SPF 30 rather than 50 is the honest target.

Specs: pH 5.5 ± 0.5 · ZnO assay 19.0–21.0% (ICP-OES) · D50 particle size 150–350 nm with <1% below 100 nm by laser diffraction, this is the release test that substantiates "non-nano" and it is a regulatory statement under EU nanomaterial definitions, not marketing copy · in vitro SPF screening (ISO 24443) at every development iteration · final SPF by ISO 24444 in vivo, n≥10; UVA-PF by ISO 24443; critical wavelength ≥370 nm · water resistance ISO 16217 if claimed · no agglomeration or settling at 40 °C/3 months.

Process: Pre-mill ZnO into isoamyl laurate + polyhydroxystearic acid, dispersion quality, not concentration, is the dominant determinant of realized SPF. Bead-mill or high-shear to target D50; verify by laser diffraction before proceeding. Emulsify at 75 °C. Cool, phase C at 40 °C. Never accept an un-verified dispersion into emulsification; agglomerated ZnO can lose 30–40% of theoretical SPF.

---

RX-12 · Urea 10% Keratolytic Body Lotion

Indication: xerosis, keratosis pilaris, ichthyotic and heel-fissure skin. Urea at 10% is dual-function (humectant below ~10%, keratolytic at and above), and is the best-evidenced body-care active on the green list.

Specs: pH 5.0 ± 0.3 · urea assay 9.5–10.5% · ammonia ≤50 ppm (headspace GC), urea hydrolyses to ammonia and CO₂, driving pH upward and generating odour; this is the defining stability liability of every urea formulation and the primary reason for the lactate buffer · viscosity 8,000–20,000 cP.

Process: Emulsify phases A (without urea) and B at 75 °C. Cool to <35 °C before adding urea, hydrolysis is strongly temperature-accelerated, and adding urea to a hot batch is the most common cause of out-of-spec ammonia at release. Adjust pH last. Buffer capacity, not initial pH, is the real control.

---

6. Pharmaceutical control strategy (ICH Q8 applied to cosmetics)

6.1 QTPP → CQA → CPP cascade

6.2 Stability program (ICH Q1A(R2) adapted)

Panel at each timepoint: appearance, odour, colour, pH, viscosity, assay, degradants, microbiological, centrifugal separation, container-closure integrity. Accelerated data supports provisional 24-month shelf life; real-time 25 °C data governs the final PAO and expiry, accelerated extrapolation is not adequate for emulsions, where physical failure modes are not Arrhenius-obedient.

6.3 Analytical methods (validate per ICH Q2(R2))

Stability-indicating HPLC-UV for niacinamide (261 nm, nicotinic acid resolved), THD ascorbate (245 nm, free AA resolved), tranexamic acid (derivatized or CAD), caffeine (273 nm), alpha-arbutin with hydroquinone at ≤10 ppm LOQ, gluconolactone (RI). LC-MS/MS for peptides. ICP-OES for ZnO and for ICH Q3D elemental impurities on all raw materials. Karl Fischer for the anhydrous SKUs. Headspace GC for ammonia in RX-12. Validation: specificity, linearity, accuracy, precision, LOD/LOQ, robustness, forced-degradation peak purity.

6.4 Manufacturing quality system

ISO 22716 GMP baseline. Purified water per USP monograph with conductivity and TOC monitoring and a sanitization loop. Raw materials on approved-vendor status with CoA plus identity confirmation on receipt (IR or refractive index), CoA acceptance without identity verification is the most common single-point failure in contract cosmetic manufacture. Formal deviation, OOS, CAPA and change-control procedures. Batch record with in-process checks at each phase transition. Retained samples across full shelf life plus one year.

---

7. Efficacy substantiation program

7.1 Claim tiering

7.2 Instrumentation and endpoints

Corneometry (hydration; 2 h and 4 weeks), Tewameter (TEWL; primary for RX-08/09/12), Cutometer (elasticity; RX-06), Mexameter + chromametry Δ ITA° and MASI (RX-05), Sebumeter (RX-03), VISIA/PRIMOS 3-D profilometry for wrinkle depth (RX-06/10), corneosurfametry and zein number for RX-01, ISO 24444/24443 for RX-11. Tape-strip lipidomics is worth the cost on RX-08 specifically, it directly evidences the physiological-lipid mechanism rather than the outcome alone.

7.3 Safety testing

HRIPT n≥100 per leave-on SKU. 21-day cumulative irritation for RX-02 (the acid) and RX-12 (urea). HET-CAM or reconstructed cornea for RX-10 and RX-01. Reconstructed-human-epidermis phototoxicity (OECD 498) for RX-04, RX-05, RX-11. Dermatologist- and ophthalmologist-tested statements only where the corresponding study exists.

A note on the chelation substitution: sodium phytate is a weaker chelant than disodium EDTA. In hard-water in-use conditions this measurably reduces both preservative potentiation and emulsion robustness. It is accepted here because EDTA carries a pollutant flag, but it means hard-water in-use testing should be added to the program, an EDTA-free formula can be stable in the lab and fail in a consumer's bathroom.

---

8. What the Yuka-95 constraint costs in efficacy, tradeoff register

This section exists because the brief asks for two things that are in genuine partial conflict: maximum efficacy on pharmaceutical standards, and a presence-based hazard score that penalizes several of the best-evidenced actives in dermatology. The design above resolves the conflict as far as chemistry allows. Where it cannot, the cost is quantified rather than concealed.

8.1 Retinoids, the largest single loss

Retinol at 0.3–1.0% is, after photoprotection, the most robustly evidenced topical intervention for photoaging: multiple randomized controlled trials show meaningful improvement in fine wrinkling, dyschromia and dermal collagen over 12–24 weeks, with an established histological mechanism. Prescription tretinoin is stronger still.

Yuka flags retinol. A 95+ formula containing any retinoid is impossible.

RX-06 substitutes matrikine peptides, niacinamide and (via RX-02) AHA/PHA turnover. Realistic assessment:

• Comparable on hydration, barrier function, tone, surface texture and radiance.
• Substantially weaker on wrinkle depth, dermal collagen density and photoaging reversal. Peptide evidence bases are smaller, more vendor-generated, and show smaller effect sizes than retinoid RCTs. Copper tripeptide-1 and palmitoyl tripeptide-1/tetrapeptide-7 have real supporting data; it is not retinoid-grade data.
• Better on tolerability: no retinization, no purging, no photosensitivity, and usable in pregnancy, a genuine and non-trivial clinical advantage for a meaningful share of users.

Do not let RX-06 carry a "retinol alternative" claim implying equivalence. It is a lower-irritation, lower-efficacy alternative on the wrinkle endpoint. That is defensible and marketable; equivalence is not.

8.2 Photoprotection

Covered in §1.1. Non-nano zinc oxide alone gives good UVB and UVA-I coverage but weaker long-UVA (370–400 nm) protection than a modern organic-filter system built on bemotrizinol or Mexoryl 400. The score ceiling is ~93. Accept 93 and ship real protection. Note that bemotrizinol received FDA approval in June 2026, expanding US formulation options, but it does not resolve the Yuka constraint, which is a hazard-flag issue rather than a regulatory one.

8.3 Vitamin C

L-ascorbic acid 15–20% at pH ≤3.5 has the deepest evidence base. It is hydrolytically unstable and its conventional stabilization stack is difficult to build all-green. RX-04 uses THD ascorbate in an anhydrous vehicle, far more stable, better skin penetration as an ester, but dependent on intracellular esterase conversion, with a smaller clinical dataset than L-AA. Genuine trade: stability and elegance for evidence depth.

8.4 Preservation

The largest risk transfer, as opposed to efficacy loss. Conventional preservation is a solved problem; this platform is not, and it moves burden onto packaging, manufacturing hygiene and shortened PAO. Expect higher COGS (airless components), tighter manufacturing controls, and shorter open-jar life. See §3.2, this is the item most likely to force a design change after benchtop.

8.5 Exfoliation

Salicylic acid is flagged, so there is no lipophilic, follicle-penetrating keratolytic in the portfolio. For comedonal acne specifically this is a real gap that gluconolactone and lactic acid do not fully close, since neither partitions into sebum. Azeloyl (RX-05) and zinc PCA (RX-03) partially compensate on the inflammatory and sebum axes.

8.6 Sensory

No fragrance, no volatile silicones, no dimethicone crosspolymer elastomers. The portfolio will read as clinical rather than luxurious. For a pharma-standard positioning that is congruent, but it should be a deliberate brand decision, not a discovered surprise.

---

9. Regulatory pathway

9.1 EU / UK

Regulation 1223/2009: Product Information File, CPSR Parts A and B signed by a qualified safety assessor, Responsible Person designated, CPNP notification. ISO 22716 GMP. RX-11 requires nanomaterial assessment, the non-nano particle-size specification is what keeps it out of Article 16 notification territory, and the D50/<100 nm data is the evidence for that position. UK: SCPN notification and a UK RP.

9.2 United States

MoCRA obligations: facility registration, product listing, adequate safety substantiation on file, serious-adverse-event reporting within 15 business days, fragrance-allergen labelling (trivially satisfied, the portfolio has none), GMP compliance as FDA rulemaking finalizes.

RX-11 is a drug in the US. Zinc oxide is a Category I OTC sunscreen active (permitted to 25%). This routes RX-11 to 21 CFR 352 monograph compliance, drug facts labelling, an NDC, drug-establishment registration and 21 CFR 210/211 cGMP, a materially heavier quality system than ISO 22716. Plan RX-11 on a separate manufacturing and release pathway from the other eleven SKUs; attempting to run it on a cosmetic QMS is the most likely regulatory failure in this portfolio.

9.3 Other

Health Canada Cosmetic Notification (RX-11 as a Natural Health Product or drug with a DIN/NPN). ASEAN/China: NMPA registration required for sunscreen and for anti-wrinkle claims; note China's efficacy-substantiation rules require in-country testing for certain claims.

---

10. Yuka score as a controlled attribute

Yuka is a third-party database that changes without notice, is not machine-readable via a published API, and rates by INCI string. A score is therefore not a stable product property, it is a dependent variable controlled by someone else. Treating it as a CQA means building an actual control system around it:

1. Locked INCI list per SKU. Any raw-material substitution, including a like-for-like vendor change that alters the declared INCI (e.g. a preservative-bearing HA solution, a trade blend carrying an undeclared glycol), triggers re-screening before approval. Trade blends are the most common way a green formula silently acquires a yellow entry.
2. Pre-launch verification. Screen the exact final INCI list in-app before packaging artwork is committed. Novel or unrated INCI names carry residual uncertainty, verify, do not assume. Ingredients in this design flagged for pre-launch confirmation: sodium cocoyl glutamate, lauryl glucoside, poloxamer 184, cetearyl glucoside, sodium acetylated hyaluronate, hydrogenated styrene/isoprene copolymer, silica dimethyl silylate.
3. Quarterly re-screening of all launched SKUs, with a documented response path if a rating changes. Assume at least one ingredient will be re-rated over a three-year horizon.
4. Supplier change-control clauses requiring notification of any INCI-affecting change.
5. Do not put the score on-pack or in paid advertising. It is outside your control, Yuka is deliberately independent of brands, and a re-rating would strand printed inventory. Formulate to it; do not build the brand promise on it.

---

11. Risk register

---

12. Development sequence

1. Feasibility (weeks 1–6). Confirm every ingredient's current Yuka rating before any benchtop work, this is the cheapest possible failure point and the one that invalidates everything downstream. Source raw materials with full INCI disclosure.
2. Benchtop (weeks 4–16). Anhydrous SKUs first (RX-04, RX-09), fastest to a validated 100 and they de-risk the sensory platform. Then the aqueous serums, then the emulsions, then RX-11.
3. Preservation gate (weeks 12–20). AET on all ten aqueous SKUs. Hard gate, no SKU advances without passing. Expect iteration here.
4. Pilot scale-up (weeks 18–30). 20–50 kg. Confirm CPPs transfer; emulsion and dispersion CQAs are the ones that break on scale-up.
5. Stability (weeks 24–76). Accelerated supports provisional launch at 6 months; real-time governs final expiry.
6. Safety and efficacy (weeks 30–70). HRIPT and ocular first, then instrumental efficacy, then clinical for the SKUs carrying the strongest claims.
7. Registration and launch (weeks 60–90). CPSR, PIF, CPNP; MoCRA listing; RX-11 on the separate drug pathway.

Critical path runs through item 3, not stability, the preservation gate is where this brief is most likely to require redesign, and it should be resourced accordingly.

---

Formulas mass-balanced and computationally verified: no duplicate INCI entries, water q.s. correct in all ten aqueous SKUs, anhydrous SKUs sum to exactly 100.00%, and the preservation platform is present in every water-containing formula. All Yuka ratings reflect the app's published penalty logic and reported ingredient classifications as of July 2026 and require in-app confirmation before benchtop work begins.